Check out your Company Bowl for anonymous work chats.
Proud to see Benchling on this list of top startups! Having a strong team — and in our case, some of the most talented, intellectually curious, and supportive people in tech and science — makes all the difference. Want to join #TeamScience? We're #hiring!
What does it mean to be on #TeamScience? Find out what Benchlings have to say about our mission and culture — and why we feel so strongly about advancing the pace of innovation for #biotech R&D.
“Our biggest priority is achieving scale. Benchling is transitioning from a startup SaaS provider to one with a significant market share.” Aysel Heckel, leader of mid-market sales, told Built In SF about what the future holds for our go-to-market team and what traits make successful candidates. #HiringNow
At Benchling, we know that fostering a culture of #ownership starts with building trust on our teams. Read more about our #engineering culture in this latest Built In #Boston story. #NowHiring
Feeling honored and inspired to be included on the Forbes #Cloud100, for the third year in a row, alongside the world’s most innovative private cloud companies.
Check it out! Benchling co-founder & CEO Saji Wickramasekara discusses the growing demand for data scientists and engineers in #biotech, and how to recruit (and retain) top engineering talent.
What if we could mine the human immune response for new therapeutics? Aridis Pharmaceuticals evaluates rare, protective antibodies from recovering patients to develop new therapies for life-threatening infectious diseases. So cool to see how Benchling customers are finding new ways of discovering and developing medicines. #BuiltOnBenchling Want to join us? We’re hiring: https://www.benchling.com/careers
#AI meets precision diagnostics at AarogyaAI, a New Delhi-based company using machine learning to diagnose drug-resistant tuberculosis and predict which drugs will work for individual patients — all from DNA sequencing results. So exciting to see how Benchling customers are leveraging AI to improve human health! #BuiltOnBenchling Want to join us? We’re hiring!!!
Check out our brand new video on Absci and how they’re harnessing AI (with the help of Benchling) to create next-generation medicines.
“If this works and is safe, this is the answer to heart attack—this is the cure.” In a momentous first, a patient has undergone gene-editing to lower their cholesterol. It's a huge milestone for Benchling customer Verve Therapeutics, who has been developing this single-dose cure for heart disease for the last several years. It's also the first-in-human use of base editing, in which a single letter of DNA is substituted for another, in this case, with the goal of permanently lowering a person's cholesterol levels.
